| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | -0.0099 | 0.8 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | 0.0088 | 0.8 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | 0.02 | 0.8 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.8 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | 0.0082 | 0.8 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |